长药控股(300391) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥103,683,885.34, representing a 75.46% increase compared to ¥59,091,762.31 in the same period last year[5] - The net loss attributable to shareholders was ¥60,812,317.13, which is a 28.01% increase from a loss of ¥47,505,902.27 in the previous year[5] - The net cash flow from operating activities was -¥71,835,780.49, a decrease of 118.90% compared to -¥32,816,721.93 in the same period last year[5] - The company's basic earnings per share were -¥0.1736, down 28.02% from -¥0.1356 in the same period last year[5] - The weighted average return on equity improved to -13.13%, a 14.59% increase from -27.72% in the previous year[5] - The net profit for the current period was a loss of ¥89,396,554.98, compared to a loss of ¥81,120,269.42 in the previous period, indicating a deterioration in profitability[34] Revenue and Costs - The increase in revenue was primarily driven by the pharmaceutical segment, which saw a significant rise in income[9] - Total operating revenue for the current period reached ¥103,683,885.34, a significant increase from ¥59,091,762.31 in the previous period, representing a growth of approximately 75.4%[33] - Total operating costs increased to ¥164,016,116.81 from ¥89,749,307.79, marking a rise of about 83.0%[34] Shareholder Information - The company reported a total of 20,224 common shareholders at the end of the reporting period[11] - The top shareholder, Changxing Shengshi Fenghua Business Co., Ltd., holds 10.11% of the shares, amounting to 35,423,600 shares[11] Financial Distress and Liabilities - The company's net assets attributable to the parent company as of December 31, 2024, were -432,840,659.21 CNY, with retained earnings at -1,589,707,417.48 CNY, indicating significant financial distress[13] - The total liabilities of the company as of the latest report were 2.553 billion CNY, compared to 2.417 billion CNY in the previous period, reflecting an increase in financial obligations[31] - The company's total equity attributable to shareholders was -493,652,976.34 CNY, highlighting a critical equity deficiency[31] - The company faces significant risks of bankruptcy and delisting if it fails to meet the Shenzhen Stock Exchange's requirements in the upcoming fiscal year[17] Cash Flow and Investments - Cash and cash equivalents at the end of the period totaled ¥3,289,786.32, down from ¥6,301,111.84 at the beginning of the period[39] - The company reported an investment cash inflow of ¥1,320,000.00, while the cash outflow for investment activities was ¥145,439.20, resulting in a net cash flow from investing activities of ¥1,174,560.80[38] - Financing activities generated a net cash flow of ¥68,545,138.96, an increase from ¥31,502,907.79 in the previous period[38] - The company received other cash related to financing activities amounting to ¥71,555,872.71, compared to ¥49,443,197.38 in the previous period[38] Restructuring and Legal Issues - The company entered pre-restructuring on January 20, 2025, with uncertainty regarding its ability to proceed with formal restructuring[14] - The court has ruled for the bankruptcy restructuring of its subsidiary, indicating potential complications for the parent company's operations[14] - As of April 22, 2025, the company's stock was subject to delisting risk warning due to financial performance issues, including negative net profit and net assets[18] Asset Overview - The total assets at the end of the reporting period were ¥2,042,496,723.36, reflecting a 2.34% increase from ¥1,995,717,642.12 at the end of the previous year[5] - The company's total assets amounted to 2.042 billion CNY, showing a slight increase from 1.996 billion CNY previously[31] Product Development - The company did not report any significant new product developments or market expansions during this period[40]